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Abbreviations 
BCODC: branched chain 2-oxo acid dehydrogenase complex. 
BTRBGD: biotin thiamine responsive basal ganglia disease  
CSF: Cerebrospinal fluid 
LS: Leigh Syndrome 
MRI: Magnetic resonance imaging 
OGDHC: oxoglutarate dehydrogenase complex  
OXPHOS: Oxidative phosphorylation. 
PDHc: pyruvate dehydrogenase complex 
SEM: Standard error of the mean  
ThTR2: thiamine transporter-2  
ABSTRACT  
Primary and secondary conditions leading to thiamine deficiency have overlapping 
features in children, presenting with acute episodes of encephalopathy, bilateral 
symmetric brain lesions and high excretion of organic acids that are specific of 
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thiamine-dependent mitochondrial enzymes, mainly lactate, alpha-ketoglutarate and 
branched chain keto-acids. Undiagnosed and untreated thiamine deficiencies are often 
fatal or lead to severe sequelae. Herein we describe the clinical and genetic 
characterization of 79 patients with inherited thiamine defects causing encephalopathy 
in childhood, identifying outcome predictors in patients with pathogenic SLC19A3 
variants, the most common genetic etiology.  We propose diagnostic criteria that will 
aid clinicians to establish a faster and accurate diagnosis so that early vitamin 
supplementation is considered. 
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Lilly, non-financial support from Gilead, outside the submitted work. 
Keywords: SLC19A3, SLC25A19, TPK1, thiamine, biotin, striatal necrosis, Leigh 
syndrome, thiamine encephalopathy, mitochondrial disease. 
Introduction  
Thiamine or vitamin B1 is a critical cofactor involved in energy metabolism and in the 
synthesis of nucleic acids, antioxidants, lipids and neurotransmitters.
1,2
  Thiamine is a 
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water-soluble essential nutrient obtained from cereals, meat, eggs, legumes and 
vegetables. In the absence of adequate thiamine intake, limited tissue storage may be 
depleted in 4 to 6 weeks.
 3
 Thiamine requires specific transporters for the absorption in 
the small intestine and for cellular and mitochondrial uptake (thiamine transporter-1, 
encoded by SLC19A2, thiamine transporter-2, encoded by SLC19A3, and mitochondrial 
thiamine diphosphate carrier, encoded by SLC25A19). Within the cellular compartment, 
thiamine is converted into thiamine diphosphate by thiamine phosphokinase (TPK1), the 
metabolically active form of thiamine, which acts as a cofactor of several thiamine-
dependent enzymes in the cytosol, peroxisomes and mitochondria (Figure 1).  
Specifically, in the mitochondria TDP acts as a cofactor of the PDHc (pyruvate 
dehydrogenase complex), OGDHC (oxoglutarate dehydrogenase complex) and BCODC 
(branched chain 2-oxo acid dehydrogenase complex). 
Infantile beriberi and Wernicke encephalopathy are rare life-threating and reversible 
causes of secondary thiamine deficiency that still occur in vulnerable populations.
4
 
Infantile beriberi presents in infants breastfed by mothers with inadequate intake of 
thiamine
5
 or receiving low thiamine-content formula
6
, whereas Wernicke 
encephalopathy is described in sick children that undergo medical or surgical 
procedures such as gastro-intestinal resections, parenteral nutrition, chemotherapy, etc.
7
  
In recent years, genetic defects in thiamine transport and metabolism have been 
described in childhood, with overlapping clinical, biochemical and radiological features 
to those observed in secondary forms, and a good response to vitamin supplementation. 
Well-defined clinical phenotypes have been recognized in the following defects:
8
 (1) 
SLC19A2 (thiamine transporter-1) causes Roger’s syndrome or thiamine responsive 
megaloblastic anemia (OMIM 249270); SLC19A3  (thiamine transporter-2, ThTR2) is 
responsible for biotin thiamine responsive basal ganglia disease (BTRBGD) (OMIM 
Page 7 of 61
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
607483); Leigh syndrome (LS); infantile spasms with lactic acidosis; and Wernicke-like 
encephalopathy; (3) TPK1 (thiamine phosphokinase) causes LS (OMIM 614458); and 
finally (4) SLC25A19 (mitochondrial thiamine pyrophosphate carrier) produces Amish 
microcephaly (OMIM 607196) and bilateral striatal degeneration and progressive 
polyneuropathy (OMIM 613710).  Interestingly, three of these genotypes (SLC19A3, 
TPK1 and SLC25A19) present with acute encephalopathy, basal ganglia lesions and 
lactic acid accumulation due to brain energy failures.
9-12
 
 
These clinical and radiological 
manifestations are indistinguishable from LS, a severe neurological disorder of brain 
energy production, caused by more than 88 genetic variants.
13,14
  
In this study we provide a global overview of the numerous genetic and acquired 
etiologies of thiamine deficiency in childhood, with specific attention to inherited 
defects of thiamine transport and metabolism. We analyze the clinical features and long-
term outcomes in a multi-ethnic cohort of seventy-nine SLC19A3, SLC25A19 and TPK1 
patients, evaluate how thiamine/biotin treatment modifies the natural history of 
SLC19A3 patients, and identify the clinical parameters that may help predict 
neurological outcome and guide further therapeutic interventions. We propose 
fundamental features to suspect inherited thiamine defects against external or secondary 
causes of thiamine deficiency, and suggest diagnostic criteria that will help clinicians to 
establish faster and accurate diagnosis so that early vitamin supplementation is 
considered. 
Methods 
Study design. We conducted a multicenter cohort study by reviewing data from patients 
with inherited defects in thiamine transport and metabolism. We invited forty-four 
investigators that had published patients with inherited thiamine defects and/or patients 
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with Leigh syndrome and mitochondrial disorders in PubMed. In total, twenty-one 
investigators accepted to participate, seventeen centers did not have patients to include 
and lastly, six colleagues did not answer or refused to participate in the study.  
A systematic analysis in MEDLINE (through PubMed) was performed to search for 
secondary causes of thiamine deficiency. We included the following keywords: #1 
beriberi, #2 Wernicke encephalopathy and #3 secondary thiamine deficiency, from 
January 2010 to February 2017. We analyzed predisposing factors, consanguinity, 
clinical, biochemical and radiological features, mortality, treatment, recovery, 
neurological and radiological sequelae.  
Study population. We included patients with two pathogenic variants of the SLC19A3, 
TPK1, and SLC25A19 genes. Patients with SLC19A2 mutations were excluded from the 
study, as they did not have significant involvement of the central nervous system. The 
responsible clinician at each collaborating center collected data via a questionnaire that 
consisted of 131 items including: demographic data, family and perinatal history, 
genetic defects, gene-related phenotype, early developmental milestones, age of disease 
onset, triggering events, clinical neuroimaging and biochemical data at disease onset, 
thiamine and biotin supplementation and follow-up. In surviving patients presenting 
with dystonia, disability was evaluated using part b of the Burke-Fahn-Marsden scale 
(BFMDS). This questionnaire evaluates the dystonic patient’s ability to perform 
everyday activities, and has been used previously in SLC19A3 patients.
15
  One hundred 
and twenty-nine patients with nuclear encoded complex I deficiency and 324 patients 
with pyruvate dehydrogenase complex (PDHc) deficiency were collected through a 
review of the research literature in order to perform a comparative survival analysis. 
The time of death of nuclear encoded complex I patients was quantified according to 
methods described by Ortigoza-Escobar et al., 2016.
16
  References of patients 
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collected with PDHc deficiency included for comparative survival analysis appear in 
supplemental material. 
Standard protocol approvals, registration and patient consent. This study was 
approved by the Ethics Committee of the Hospital Sant Joan de Déu, Barcelona, Spain. 
Informed consent was obtained from all patients.  
Statistical analysis. Statistical analyses were performed using IBM SPSS Statistics 23 
software (IBM Corp., Armonk, NY, USA). The quantitative variables were reported 
either in terms of the normal distribution mean, standard error of the mean (SE) and the 
range; or in terms of the median and interquartile range (IQR). The Mann-Whitney U 
test was applied to evaluate differences in numerical variables between groups. The chi-
square test and Fisher’s exact test were used to test the association between categorical 
variables. Multiple logistic regression analysis was performed to further investigate the 
relationship between the binary response variable and potential predictors of survival. 
The Kaplan-Meier survival analysis was used to compare the survival rates of the 
SLC19A3-deficient patients, patients with PDHc and nuclear-encoded complex I-
deficient LS. Differences in survival between the groups were evaluated using the log 
rank test. All statistical tests were two-sided and performed at a 0.05 significance level.   
Results 
1. Inherited thiamine defects  
We identified 70 patients with SLC19A3 disease, 4 patients with TPK1 disease and 5 
patients with SLC25A19 disease. The patients were diagnosed at twenty-one centers: 
UK (n=4), USA, Germany and Finland (n=3), Saudi Arabia (n=2), The Netherlands, 
Spain, Israel, France and Sweden (n=1). Genotypes were established in all patients, 
including P76 who had a similar disease course to his sibling with TPK1 deficiency and 
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in whom the same mutations were confirmed using residual DNA. Complete clinical 
data sets were available in 65/70 patients with the SLC19A3 mutation and in all patients 
with SLC25A19 and TPK1 mutations. Magnetic resonance imaging (MRI) data were 
available in all except seven SLC19A3 patients who were diagnosed post-mortem (P39 
to P45). None of the patients were found to have additional clinical or biochemical 
abnormalities suggestive of other genetic diseases. 
1.1. SLC19A3  
The 70 patients with SLC19A3 deficiency (mean age at assessment ± SE:  9.5±0.9 years, 
range 1 month – 40 years old, 36 males, 51%) were born between 1975 and 2015. Of 
these, 63 (90%) had been previously reported. Consanguinity was reported in 51 (73%) 
patients and 44 (62%) had other affected family members. Arabs formed the largest 
ethnic group (58/70, 82%: Saudi Arabian n=41, Moroccan n=11, Iraqi n=3, Kurdish 
n=2, Kuwaiti n=1), followed by White European (10/70, 14%: Spanish n=3, Portuguese 
n=2, German n=2, Finnish n=2, Hispanic n=1), and African/Afro-Caribbean (2/70, 
2.8%) (Supplementary Table 1). 
Clinical phenotype 
Supplementary Table 1 summarizes the demographic, genetic, clinical and radiologic 
features in the entire patient cohort. The frequency of the main clinical features appears 
in Figure 2. Fetal distress was noted in P2, P29 and P61 and acute presentation during 
the newborn period (around 4 weeks of age in all cases) was reported in 9 (12%) 
patients. In the vast majority the developmental milestones were average, except in 7 
cases (P28, P29, P53, P57, P60, P61 and P66) 
The median age at disease onset was 3 years, the range was 1 month – 34 years and the 
IQR was 1 – 2.8 years. The trigger events (39/70 patients, 55%) were viral (n=30) or 
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bacterial (n=4) infection, trauma (n=3), profuse exercise and vaccination (n=1, each). 
Fifteen (21%) patients were classified as LS and fifty-three (75%) as BTRBGD due to 
their positive responses to thiamine/biotin treatment. Twins (P35 and P36) with a 
positive family history (siblings of P34) were identified before the onset of symptoms. 
Twenty-six patients experienced more than one encephalopathic episode before the 
initiation of vitamin supplementation (2 episodes n=12, 3 episodes n=7, 4 episodes n=4 
and 5 or more episodes n=3 [P32, P33 and P49]). Most episodes of neurological 
deterioration were triggered by infection or stress. Intensive care was required in 5 of 
the patients (P1, P3, P48, P68, and P69).  
A minority of patients (10/62, 16%) had an insidious onset of symptoms characterized 
by psychomotor regression, hyperactivity and attention deficit, unsteady gait, toe 
walking or stiffness of the limbs.  
Systemic features of mitochondrial disease (cardiomyopathy, cardiac conduction 
defects, renal tubulopathy or facial dysmorphism) were absent in our series. P4 
developed a steroid-sensitive nephrotic syndrome. 
Seizures were classified according to the International League Against Epilepsy (ILAE) 
as follows: generalized seizures (n=31), focal seizures (n=6, including two patients [P30 
and P31] with epilepsia partialis continua), epileptic spasms (P64, n=1) and West 
syndrome (P48, n=1). Thiamine and biotin treatment controlled seizures in patients 
effectively, except in P38, P53 and P59, who also received antiepileptic drugs, and P49, 
P61 and P64, who developed drug resistant epilepsy. 
Ancillary testing 
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Few patients showed increased CSF lactate (5/29 patients, mean±SE: 3.7±1 mmol/L, 
range 2.1-7.1 mmol/L; NV<2), increased blood lactate (20/40, mean±SE: 4.1±0.4 
mmol/L, range 2.1-8.6 mmol/L, NV<2), metabolic acidosis (6/36) and increased blood 
alanine (4/15, mean±SE: 666±129 µmol/L, range 450-1037 µmol/L, NV<439). The 
lactate/pyruvate ratio was below the normal limit in two patients. Increased blood 
lactate levels were negatively correlated with the age of onset in the SLC19A3 patients 
(p <0.001).  
Abnormal organic acid profiles were recorded in 8/50 patients, with high excretion of 
isobutyric, 2-OH-isovaleric and 2,4-di-OH-butyric (P1), alpha-ketoglutaric (P2), lactic 
(P34 and P52), 3-OH-butyric (P37), 2-OH-glutaric, glutaric, succinic and 2 keta adipic 
acid (P41) and 4-OH-phenyllactic  (P46).  
MRI and MRS were available in 61/70 (87%) and 43/70 (61%) patients, respectively. 
All symptomatic patients had lesions at onset, involving bilateral caudate (n=55), 
putamen (n=57), cortico–subcortical areas of the cerebral hemispheres (n=40), 
ventromedial region of the thalamus (n=38), cerebellum (n=23), brainstem (n=14), 
periaqueductal region (n=12), spinal cord (n=11) and the globus pallidus (n=6) (Figures 
2 and 3). Acute MRIs indicated swelling and chronic MRIs indicated volume loss and 
necrotic changes. MRS detected a lactate peak in 55% (24/43) patients within the 
affected areas. Stroke-like lesions or mammillary body lesions were not identified.  
Statistical analysis showed that deceased patients had more frequent involvement of the 
globus pallidus and brainstem than surviving patients (3/15 vs. 3/55, Mann–Whitney U 
test, p=0.001; and 4/15 vs. 10/55, Mann–Whitney U test p=0.009, respectively).  
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OXPHOS activity was normal in the muscle and skin biopsies of 6 patients, with the 
exception of P41 who showed 56% of complex IV activity in fibroblasts. None of the 
patients had ragged red fibers.  
Treatment and outcome 
Fifty-one patients received vitamin supplementation during the acute encephalopathic 
episode. The time from disease onset to vitamin initiation was very broad (median 14 
days, IQR: 4–180 days). Forty-four patients had a significant clinical recovery within 
hours or days of vitamin initiation: they regained alertness, improved feeding, had a 
better control of seizures and gradually recovered previously acquired milestones. Four 
more patients showed a mild improvement and three patients did not improve at all.  
Fifty-five patients were alive at the time of recruitment (mean follow-up 5.2±0.7 years, 
range 2 weeks-22 years). All of them received thiamine (thiamine hydrochloride, mean 
dose 20 mg/kg/day, range 5 to 55) and forty-seven received biotin (mean dose 5 
mg/kg/day, range 1 to 30).  Both vitamins were administered orally in most patients, 
although some patients received intravenous supplementation in the acute episode. The 
neurological examination was normal in twenty-six patients at the time of assessment 
and they were symptom-free, whereas twenty-seven had developed some neurological 
sequelae (Supplementary Table 1). No further decompensating episodes of 
encephalopathy, dystonia or other neurological symptoms were recorded after vitamin 
supplementation in these patients, except for P61 who received inadequate vitamin 
doses. Additionally, blood alanine levels and the organic acid profiles in urine were 
normal in patients receiving vitamin supplementation. Only P52 had slightly elevated 
blood lactate (2.3 mmol/L). The twins (P35 and P36) who were treated pre-
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symptomatically with thiamine alone were symptom-free at the time of assessment (5 
years).  
Fifteen patients (21%) died, the majority of them from central respiratory failure 
(6.1±1.9 years at death, range: 4 weeks - 20 years). Deceased patients were younger at 
onset compared to surviving patients (mean age±SE 2.4±1.1 years vs. 5.4± 0.9 years, 
Mann–Whitney U test, p=0,005). Among the fifteen deceased patients, four had 
received vitamin supplementation (P1, P30, P41 and P49).  
Disability score  
The BFMDS questionnaire was administered to 34 SLC19A3 patients with dystonia 
(9.8±1.8 points (mean ±SE), range 0–30 points). Higher BFMDS scores were identified 
in patients who had a previous history of developmental delay (19.5±4.1 vs. 7.7±1.7, 
Mann–Whitney U test, p=0.017) and in patients with disease onset before 6 months of 
age (23.7±2.8 vs. 7.9±1.7, Mann–Whitney U test, p=0.01). A positive and almost 
significant correlation was observed between the BFMDS scores and the time from 
disease onset to thiamine initiation (Pearson correlation, r=0.340; p=0.053) (Figure 
4D). 
Survival analysis 
In the Kaplan-Meier analysis (Figure 4), treated SLC19A3 patients had a longer mean 
survival length than non-treated patients (A) (28.99 vs. 17.23 years, log rank test, 
p<0.0001). Additionally, mean survival length was longer in homozygous c.1264A>G 
SLC19A3 patients than in patients with other mutations (B) (29.88 vs. 15.52 years, log 
rank test, p<0.0001). Homozygous c.1264A>G patients were comparable to patients 
with other mutations with respects to age at disease onset and age at treatment initiation. 
However, a significant difference was observed between both groups in the number of 
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treated patients (39/44 (88%) treated c.1264A>G patients versus 13/22 (59%) treated 
patients with other mutations, p=0.006). Mean survival length was longer in the 70 
SLC19A3 patients than in 129 patients with nuclear-encoded complex I deficiency (C) 
(28.0 vs. 11.5 years, log rank test, p<0.001). Similar results were obtained when the 
SLC19A3 and Complex I patients were divided into two age groups: those with disease 
onset before 6 months (11.3 vs. 2.9 years, Log rank test, p=0.004) and those with a later 
onset (log rank test, 33.3 vs. 22.6 years, p=0.003). No significant differences were 
observed in the mean survival length between 70 SLC19A3 and 324 PDHc patients in 
both age groups. However, an almost significant difference was observed when 
selecting male PDHA1 patients.  
SLC19A3 gene mutations 
We identified 13 SLC19A3 pathogenic mutations (Supplementary Table 1, Figure 4) 
in the 70 patients. Five of these mutations were novel (c.91T>C, c.157A>G, 
c.503_505delCGT, c.516_delC and c.833T>C). Fifty-nine patients were homozygous 
for the following missense mutations: c.1264A>G (n=, 47), c.20C>A (n=7), c.157A>G 
(n=3), c.68G>T (n=1) and c.541T>C (n=1). Eleven patients were compound 
heterozygotes. The most frequently occurring mutation in our cohort, c.1264A>G, was 
present in patients with Arab ethnic backgrounds, including Saudi Arabian, Moroccan, 
Kurdish and Kuwaiti patients. The next most common mutation, c.20C>A, occurred 
exclusively in subjects from the province of Al Hoceima in Northern Morocco (n=7, 3 
pedigrees).
9
 The splice mutation c.980-14A>G was observed in 5 compound 
heterozygote individuals, all of them of White European origin.  
1.2. SLC25A19 
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We recruited 4 consanguineous Arabic patients from Israel
 
(homozygous for 
c.373G>A)
12
 and a new White European German patient diagnosed by our group (P75). 
The phenotype of this girl, age 21 years, was similar to previously reported cases 
(Supplementary Table 1). The symptoms were triggered by febrile illness between 20 
months and 6.5 years of age, and consisted of acute encephalopathy, dysarthria, and 
episodic flaccid weakness. They had elevated levels of lactate in the CSF at onset (2.9–
4.2 mmol/L, NV<2 mmol/L) but normal systemic mitochondrial biomarkers. MRI 
showed T2 hyperintensity and necrosis in the caudate and putamen in all patients. 
Additionally, P74 had T2 hyperintensity (cavitated lesion) in the medial thalamus.  
Thiamine treatment (400 – 600 mg/day) administered three years after onset led to 
substantial improvement in peripheral neuropathy and gait in P71 and P72, whilst P74 
and P73, treated 9 and 12 years later, respectively, continued to have significant 
ambulatory impairment. All patients are currently alive. They have mild to severe 
bilateral pes equinus, axonal polyneuropathy and dystonia. The disease severity was 
clearly milder in P71, P72 and P75, supporting the efficacy of thiamine treatment in 
preventing further disease progression.  
Interestingly, P73 stopped thiamine treatment due to an apparent lack of benefit. Four 
years later, a severe episode of flaccid paralysis occurred with fever, and intravenous 
thiamine (1.500 mg) led to clinical recovery within 24 hours.  
1.3. TPK1 
Four TPK1 patients (P76, P77 and P79, previously reported),
17,18 
suffered from LS 
triggered by febrile illness between one month and 2.5 years of age (Supplementary 
Table 1). Brain lesions developed in the cerebellum and dentate nuclei (n=4), striatum 
(n=3), thalamus, globus pallidus (n=2), brainstem and spinal cord (n=1). P76 showed 
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lactic acidosis (3.0 mmol/L, NV < 1.77 mmol/L) whilst none had increased lactic acid 
in the CSF. Increased excretion of organic acids was recorded in 3 out of 4 patients: 
lactic acid (P76), glutaric acid (P77) and mildly increased alpha-ketoglutaric acid and 
dicarboxylic acid (P79). P76 and P78 who did not receive thiamine supplementation 
died at the age of 29 and 6 months, respectively. P77 and P79 are currently 4 and 7 
years old, respectively. P77 receives a combination of thiamine (15 mg/kg/d), biotin (1 
mg/kg/d, P77) and ketogenic diet and P79 receives thiamine (500 mg/day) alone. Both 
patients show severe neurologic sequelae, with spasticity, hypotonia, dystonia, 
developmental delay and high scores on the BFMDS (27 and 14, respectively).  
Secondary thiamine deficiency 
A total of 153 patients (beriberi: N=88; Wernicke encephalopathy: N=65) were 
collected, age between 2 weeks and 17 years of life.
 4, 19-42
 A summary of the main 
characteristic features collected in our database is provided in Figure 6. Predisposing 
factors were reported in 100% of cases. Systemic, cardiovascular and respiratory 
symptoms were recorded in all patients with beriberi and a few cases with Wernicke 
encephalopathy. The majority of cases showed increased blood 53/55 (96%) and CSF 
lactate, 12/13 (92%) and metabolic acidosis: 17/34 (50%). Low blood thiamine levels 
were detected in 100% of cases that were analyzed. The thalamus, periaqueductal region 
and mammillary bodies were more frequently involved, as opposite to patients with 
inherited thiamine defects, who showed more frequent alterations in the caudate and 
putamen. Clinical improvement after thiamine supplementation was constant, and less 
than 20% showed mortality or neurological sequel.   
Discussion 
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Thiamine diphosphate, the metabolically active form of thiamine, is essential for energy 
production in the central nervous system. In brain regions with high metabolic demands, 
thiamine deficiency due to exogenous (nutritional) or endogenous (genetic) defects can 
trigger a metabolic crisis, and Wernicke’s encephalopathy is a model of cerebral 
thiamine deficiency.
43
 Primary and secondary conditions leading to thiamine deficiency 
have overlapping features in children, both presenting with acute episodes of 
encephalopathy, bilateral symmetric brain lesions, and biomarkers of mitochondrial 
dysfunction, such as lactic acid accumulation in different tissues and high excretion of 
organic acids. In both scenarios, early thiamine supplementation may lead to clinical 
recovery within a few hours or days, and brain lesions may be reversible on MRI.  
In our international study group of 79 patients with inherited thiamine defects, the vast 
majority of children were born to consanguineous patients, they presented between the 
age of 1 and 6 years in the context of a febrile illness, with acute/recurrent 
encephalopathy, basal ganglia lesions, dystonia, hypotonia, spasticity, ataxia and 
seizures. Lactic acid accumulation in the CNS was identified by MRS in half of the 
SLC19A3 patients, and in all SLC25A19 cases by CSF analysis, suggesting brain energy 
failure, as in other cases of Leigh encephalopathy.
13
 Also, abnormal organic acids were 
identified in a few SLC19A3 and TPK1 cases. These included organic acids that were 
specific of thiamine dependent mitochondrial enzymes, such as lactic acid (PDHc), 
alpha-ketoglutarate (OGDHC) and branched chain keto-acids (BCODC), and other non- 
specific organic acids caused by generalized mitochondrial dysfunction. These 
biomarkers did not predict outcome in our series.  
Fundamental features to suspect primary thiamine defects against secondary etiologies 
were the frequency of consanguineous families, the absence of predisposing factors for 
Page 19 of 61
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
beriberi and Wernicke encephalopathy, the lack of cardiovascular or respiratory 
features, and the sparing of mammillary bodies on MRI (Figure 6).  
A characteristic feature that distinguished patients with mutation in SLC25A19 from the 
other genetic defects was the presence of peripheral neuropathy. This phenotype was 
initially described in Spiegel et al., 2009,
12
 and to our knowledge no further patients 
have been reported since then. We identified a novel missense variant in the SLC25A19 
gene in a 20-year-old woman with striatal necrosis and peripheral neuropathy, thus 
providing clinical evidence to the recognition of this phenotype. In contrast to SLC19A3 
and SLC25A19, patients with mutation in TPK1 had an earlier onset of symptoms, they 
showed variable response to thiamine supplementation, and developed a more severe 
phenotype with higher morbidity and mortality.  
Based on the frequency of the main clinical and radiological features, and on specific 
biomarkers, we propose diagnostic criteria for the three known inherited thiamine 
defects with prominent neurologic involvement (Table 1). Total thiamine levels in 
blood are reduced in patients with secondary deficiencies, but are normal in genetic 
conditions 
44-46
, in which the quantification of thiamine isoforms, either in blood, CSF, 
fibroblasts or muscle cells, is critical for the diagnosis.
13,47
  
More than one third of SLC19A3 patients had several recurrent encephalopathic 
episodes before vitamin supplementation. Most of them were born after the first 
description of the disease by Ozand et al. in 1998,
48
 suggesting that this is an under 
diagnosed disorder. Thiamine and biotin supplementation led to prompt and significant 
clinical recovery in most SLC19A3 patients. Survival analyses showed that the mean 
survival length was longer in patients who received thiamine and biotin compared to 
non-treated patients. No further episodes of encephalopathy, dystonia or other 
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neurological disturbances were noted after vitamin supplementation. Additionally, 
patients had effective control of seizures without the need of antiepileptic drugs and 
nonspecific biomarkers of mitochondrial dysfunction remained within normal limits. 
More importantly, half of treated patients had no disability at all, and neurological 
examination was normal at the time of assessment. A positive correlation was observed 
between the disability scores and the time spent between disease onset and thiamine 
initiation, meaning that the earlier the therapeutic intervention, the lower the sequel 
observed, although this data did not reach statistical significance. It was likely that the 
deceased patients with severe disabilities were missing relevant data, representing an 
important bias against a significant correlation in this analysis. 
We identified clinical parameters that may help predict neurological outcomes before 
the initiation of vitamin supplementation. Patients with symptoms presenting within the 
first 6 months of life had a shorter survival curve and higher scores on the disability 
scale. Moreover, the distributions of brain lesions in the deceased SLC19A3 patients 
were more diffuse, with a significantly higher involvement of the globus pallidus and 
brainstem. This is in accordance with previous reports that indicate a subgroup of 
patients with thiamine transporter 2 deficiency presenting with fatal infantile Leigh 
syndrome, who died very early in the disease course, or were left with severe 
neurological sequel and extensive brain injury despite the initiation of vitamin 
treatment.
9,49
 In our cohort, four children died despite vitamin supplementation. Pre-
treatment predictors of poor responses in these patients were extensive brain 
involvement (P49), early onset of the disease (P41) or the co-occurrence of septicemia 
in a child receiving intensive care (P1).  
Based on these data, we believe that patients presenting with Leigh syndrome should be 
treated with a vitamin cocktail including thiamine and biotin, as the phenotype of 
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inherited thiamine defects may be clinically indistinguishable from other genetic 
disorders leading to Leigh encephalopathy. However, therapeutic interventions should 
be individualized in those cases presenting clinical predictors of poor neurological 
recovery.  
SLC19A3 patients showed longer survival length than patients with complex I 
deficiency, with more than 60% of the SLC19A3 patients surviving at 20 years of age.  
Previous studies have demonstrated poor survival rates in LS patients. 
50-55
 Factors 
associated with poor prognosis in LS patients were the onset of symptoms within the 
first 6 months, the presence of cardiomyopathy
56
 and brainstem involvement.
50
 As 
opposite to these features, SLC19A3 patients in our series had a median age at disease 
onset of 3 years, they did not show cardiac involvement, and brain stem lesions were 
observed in a minority of cases. More importantly, thiamine supplementation prolonged 
survival in SLC19A3 patients, whereas no effective treatment is available for complex I 
deficiency patients. We didn't observe differences on survival between SLC19A3 and 
PDHc patients; however, an almost significant difference was observed when selecting 
male patients with PDHA1 deficiency, which are known to have a poorer survival than 
females. PDHc patients benefit from ketogenic diet
57
 and thiamine supplementation,
58
 
which reduce neurological features and the frequency of hospitalizations.  
A high proportion of SLC19A3 patients in our cohort were homozygous for the 
missense variant c.1264A>G, all of them belonging to the Arab ethnic group. These 
patients had a longer survival than patients with other mutations. The higher proportion 
of patients receiving thiamine and biotin in the group of homozygous c.1264A>G 
patients compared to patients with other mutations may account for these differences. In 
line with this observation, transfection studies demonstrated that the c.1264A>G 
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mutation led to a protein with null-transport activity, 
59
 which is difficult to correlate 
with a more benign phenotype.  
Among patients from European countries, we identified four compound heterozygous 
cases with c.74dupT/c.980-14A>G that had in common a late disease onset, three of 
them in adolescence and adulthood, with an excellent response to thiamine.
60,61 
Likewise, a recently described patient with the same mutations presented an adult-onset 
subacute leukoencephalopathy with an effective response to thiamine.
62
  
Our results confirm previous reports on a characteristic pattern of brain injury in 
inherited thiamine defects 
9-12, 17, 19, 45, 60, 61, 63 
that will help in the early recognition and 
differential diagnosis. The majority of SLC19A3 patients showed striatal lesions in 
combination with other affected brain areas, including cortico–subcortical regions of the 
cerebral hemispheres, ventromedial thalamic nuclei, cerebellum, brainstem, 
periaqueductal region, spinal cord and globus pallidus, in order of decreasing frequency. 
As previously mentioned, deceased patients had a greater involvement of the brain stem 
and globus pallidum. Lesions in the respiratory centers, located in the medulla 
oblongata and pons, may be responsible for acute respiratory failure, the most frequent 
cause of death in this cohort, as in other LS patients. Moreover, bilateral lesions in the 
globus pallidus were also related to severe dystonia and poor prognosis in patients with 
glutaric aciduria type I and in carbon monoxide intoxication.
64,65
 Isolated striatal 
necrosis was a common feature of SLC25A19 patients. In contrast, TPK1 patients 
showed basal ganglia lesions in combination with involvement of the cerebellum and 
dentate nuclei.   
The small size of the sample was an important limitation for this study. Also, 
recruitment was restricted to published cases and individual centers, leading to a 
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possible selection bias toward more severe presentations. These are common limitations 
for research in rare diseases, where the limited number of patients hampers the 
recognition of the full spectrum of severities. Also, a more accurate assessment on 
neurodevelopment should be warranted in future studies.  
In summary, this international study describes the natural history of seventy-nine 
patients with inherited defects in thiamine transport and metabolism. We confirm that 
thiamine defects manifest with acute brain injury in the first decade of life in the vast 
majority of patients. We demonstrate how vitamin supplementation modifies the 
survival curve of SLC19A3 patients, and identify statistically significant predictors of 
neurological outcome that may guide clinicians in further therapeutic interventions. Our 
study indicates a better prognosis than other causes of Leigh syndrome, encouraging 
clinicians to suspect the disease and to make an early diagnosis and accurately prescribe 
treatment. We also contribute with diagnostic criteria for inherited thiamine defects and 
help differentiate them from secondary causes of thiamine deficiency. 
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Figures 
Figure 1. Schematic layout of the thiamine transport and metabolism. There are 
four known forms of thiamine in humans, free non-phosphorylated thiamine (free-T, 
purple balls) and its phosphate esters: thiamine monophosphate (TMP, green balls), 
thiamine diphosphate (TDP, red balls), and thiamine triphosphate (TTP, non-
represented). Although at high concentrations, thiamine absorption is via passive 
diffusion, thiamine is absorbed in the small and the large intestine and transported 
across the blood-brain barrier using several well-known transporters: SLC19A1 (folate 
transporter) SLC19A2 (thiamine transporter-1), SLC19A3 (thiamine transporter-2), 
SLC44A4 (human TDP transporter), SLC22A1 (OCT1, organic cation transporter 1) and 
SLC35F3. At that point intracellular free-T is converted to TDP, which is the 
metabolically active form of the vitamin, by TPK1 (thiamine pyrophosphokinase) and 
transported inside the mitochondria by the SLC25A19 (mitochondrial TDP transporter). 
Human TDP-dependent enzymes comprise TK (transketolase), HACL1 (2-hydroxyacyl-
CoA lyase 1), PDHc (pyruvate dehydrogenase complex), OGDHC (oxoglutarate 
dehydrogenase complex) and BCODC (branched chain 2-oxo acid dehydrogenase 
complex).  
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Figure 2. Major clinical features and neuroimaging results in 70 SLC19A3-
deficient patients. A.  Encephalopathy defined as lethargy, irritability, agitation, 
vomiting, continuous crying, coma leading to ventilatory support, etc. Status dystonicus 
defined as the need of specific management, such as admission to pediatric intensive 
care unit, sedation and ventilatory support, benzodiazepines, baclofen, clonidine, 
anticholinergic, chloral hydrate, DBS, etc. Spasticity includes hyperreflexia and signs of 
Babinski reflex. Liver disease defined as increased liver enzymes, liver failure or 
hepatomegaly. The number of patients is plotted on the x-axis and the symptoms and 
signs are plotted on the y-axis. B. Most patients presented a characteristic radiological 
pattern with hyperintensities in the caudate, putamen, ventromedial region of thalamus 
and diffuse cortico-subcortical areas. Statistical analysis indicated that deceased patients 
had more frequent involvement of the globus pallidus (3/15, 20%, vs. 3/55, 5%, 
p=0,001) and brainstem (4/15, 26% vs. 10/55, 18%, p=0,009) than surviving patients.  
Figure 3. MRI patterns in patients with secondary and inherited thiamine defects. 
Wernicke encephalopathy. Axial T2W, sagittal and coronal FLAIR images show 
bilateral symmetric involvement of dorsal medial thalamus, periaqueductal gray matter, 
mammillary bodies (white arrow) and patchy cortical and subcortical hyperintensities. 
SLC19A3. Axial and coronal T2W images show bilateral symmetric involvement of the 
putamen and thalamus along with patchy cortical and subcortical hyperintensities. 
SLC25A19.  Axial T2W and T1W images show cystic necrosis of the caudate and 
putamen. TPK1. Axial and coronal T2W SE images show involvement of the posterior 
putamen and dentate nuclei (gray arrow). 
Figure 4. The figure shows Kaplan-Meier survival curves (A, B, C) and the 
correlation between the Burke-Fahn-Marsden Disability Scale and the time 
elapsed between disease onset and thiamine supplementation in SLC19A3 patients 
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(D). A. Comparison between treated (n=51) vs. untreated (n=19) SLC19A3-deficient 
patients; log rank test p<0.0001. B. Comparison between c.1264A>G homozygous 
mutation (n=44, 39 (88%) treated patients) vs. other mutations (n=22, 13 (59%) treated 
patients) in SLC19A3-deficient patients; log rank test p<0.0001.  C. Comparison 
between SLC19A3 patients (n=70), nuclear-encoded complex I deficient Leigh 
syndrome (n=129) and male PDHc deficient patients due to PDHA1 deficiency 
(n=145). When comparing SLC19A3 and nuclear-encoded complex I deficient Leigh 
syndrome, differences reach statistical significance (log rank test p<0.001).  When 
comparing SLC19A3 and male PDHc patients, differences did not reach statistically 
significance (log rank test p=0.06). D. Correlation between the BFMDS (y-axis) and the 
time elapsed between disease onset and thiamine supplementation (x-axis, days, log-
scale) in SLC19A3 patients (r=0.34, p=0,053). 
Figure 5. Pathogenic mutations in the human thiamine transporter type-2 
(SLC19A3) and the human mitochondrial thiamine pyrophosphate transporter 
(SLC25A19). A schematic diagram of these proteins illustrating 25 and 3 mutations 
reported to date. †: novel unreported mutations identified in this study, ‡: most common 
mutation.  
Figure 6.   Clinical, biochemical and radiological characteristics of patients with 
inherited thiamine defects (N=79) compared to secondary thiamine deficiency 
(N=153) 
Tables  
Table 1. Suggested criteria for diagnosis of inherited thiamine defects with 
prominent neurologic involvement 
Supplementary material  
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Supplementary Table 1. Demographic, clinic, genetic and radiologic features of 78 
patients with SLC19A3, SLC25A19 and TPK1 deficiency 
*Other sibling affected not included in this study, NA = Not available, SYMPTOMS 
AT ONSET/ OUTCOME: Encephalopathy (E), Paroxysmal Ataxia (A), Hypotonia 
(H), Tremor (T), Dystonia (D), Status dystonicus (Sd), Chorea (Ch), Opistothonus (O), 
Rigidity (Akinetic-rigid syndrome) (Ak), Spasticity (S), Nystagmus (N), Strabismus 
(Sb), Ptosis (Pt), Ophtalmoplegia (Oph), Diplopia (D), Vertigo (V), Hypoaesthesia (Hy) 
Dysarthria (Dth), Dysphagia (Dph), Weight loss (W), Respiratory failure (Res), Liver 
disease (Hep), Rhabdomyolisis (Rab), Dysautonomia (Dys), Jaundice (J), Seizure – 
including focal, generalized and infantile spasms (Sz), Peripheral neuropathy  (Pn), 
Developmental arrest (Rg), Movement disorder (MD), Spasticity (S), Intellectual 
disability (ID), Scoliosis (Sch), microcephaly (m).  ABNORMAL REGIONS ON 
NEUROIMAGING: Caudate (C), Putamen (P), Globus pallidus (Gp), Thalamus (T), 
Corticosubcortical (Cs), Cerebellum (Cb), Brainstem (B), Periqueductal (Pq), Spinal 
cord  (SC), Lactate on MRS (Lactate), Cerebral atrophy (CA), Cerebellar atrophy 
(CbA). PHENOTYPES Leigh Syndrome (LS), Biotin responsive basal ganglia disease 
(BTRBGD), Asymptomatic 
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CASE REF CONSANGUINITY-
FAMILY HISTORY 
(Yes (Y), No (N)) 
ETHNICITY  
ONSET/ 
CURRENT 
AGE  (Years) 
MUTATION  
ALLELE 1  
MUTATION  
ALLELE 2 
PHENOTYPES SYMPTOMS at onset 
TRIGGER 
EVENT at 
onset  
ABNORMAL REGIONS ON 
NEUROIMAGING 
OUTCOME  DISABILI
TY 
SCORE 
             
P1 27 
N White European-Spanish 13mo/- c.1079dupT/p.L360Ffs*11 c.980-14A>G/p.G327Dfs*8 LS E, H, T, D, Ch, O, N, J, Hep, W, Res, 
Dph, A 
Viral infection C,P,T,Cs, Lactate Deceased at 14 
mo  
- 
P2 27 Y Arab-Moroccan 1mo/3y c.68 G>T/p.G23V c.68 G>T/ p.G23V LS E, H, T, D, O, S, Dph  None P, T, Cs, Lactate Alive-MD, E, S, M 16 
P3 27 
N-sibP4 White European-Spanish 17y/25y c.74dupT/p.S26Lfs*19 c.980-14 A>G/p.G327Dfs*8 BTRBGD 
E, H, T, D, Sd, Ak, S, N, Rab, Dys, Dth, 
Hy, V, D, Pt   
Profuse 
exercise 
C,P,T,Cs 
Alive-normal, D 
5 
P4 27 N-sibP3 White European-Spanish 4y/4y c.74dupT/ p.S26Lfs*19 c.980-14 A>G/p.G327Dfs*8 BTRBGD E, H, T, D, Dph, Dth   None C,P,T, Lactate Alive-normal 1 
P5 7 
Y-sibP6 
Arab-Saudi Arabian 
2y/7y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD 
E, A, H, T, D, S  
Viral infection C,P,T, Cs, Lactate 
Alive-normal 
0 
P6 7 Y-sibP5 Arab-Saudi Arabian 8y/12y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, T, D, S, Oph, Dth, Dph, Sz Viral infection C,P,T, Cs, Cb, B, Pq, SC, Lactate Alive-normal 3 
P7 7 
Y-sibP14 
Arab-Saudi Arabian 
13y/- c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD 
E, H, T, D, S, Oph, Dth, Dph, Res, 
Rab, Sz Viral infection C,P,T, Cs, Cb, B, Pq, SC, Lactate 
Deceased at 13 y 
- 
P8 7 Y Arab-Saudi Arabian 13y/16 c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, H, T, D, S Oph, Dth, Dph, Res, Sz Viral infection C,P,T, Cs, Cb, B, Pq, Lactate Alive-S, ID, D 29 
P9 7 Y-sibP10 Arab-Saudi Arabian 6y/10y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, T, D, S, Dth, Dph  Viral infection C,P, Lactate Alive-ID, D 10 
P10 7 Y-sibP9 Arab-Saudi Arabian -/16y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD NA NA C,P,T, Cs, Cb, B, Pq, SC, Lactate Alive-not known - 
P11 7 Y Arab-Saudi Arabian 50mo/8y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, T, D, S, Oph, Dth, Dph, Sz None  C,P,T, Cs, Cb, B, Pq, SC, Lactate Alive-normal 0 
P12 7 Y Arab-Saudi Arabian -/7y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD NA NA C, P, T, B, SC Alive-normal - 
P13 7 
Y 
Arab-Saudi Arabian 
8y/12y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, D, S, Oph, Dth, Dph, Sz Viral infection C,P,T, Cs, Cb, B, SC,  Lactate 
Alive-normal 
0 
P14 7 Y-sibP7 Arab-Saudi Arabian 11y/32y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, D, S, Dth None C, P Alive-S, ID, D 10 
P15 7 
Y 
Arab-Saudi Arabian 
11y/13y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, D, S, Oph, Dth, Dph, Sz Viral infection C,P,T, Cs, Cb, SC 
Alive-normal, D 
6 
P16 7 Y Arab-Saudi Arabian 2y/5y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, D, S, Dth, Dph, Sz Viral infection C,P,T, Cs, Cb, B, SC, Lactate Alive-S, ID, D 8 
P17 7 Y Arab-Saudi Arabian 3,5y/15y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, D, S, Dth, Dph, Sz Viral infection C, P Alive-ID, D 8 
P18 7 Y Arab-Saudi Arabian 11y/13y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, T, D, S, Oph, Dth Viral infection C,P,T, Cb Alive-normal 2 
P19 7 Y-* Arab-Saudi Arabian 3y/6y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, D, S, Dth, Dph, Sz Trauma C,P,T, Cs Alive-normal 2 
P20 7 Y-P21 Arab-Saudi Arabian 8y/11y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, D, S, Oph, Dth, Dph, Sz Viral infection C, P, T, Cs, Cb, Pq, Lactate Alive-normal 2 
P21 7 
Y-P20 
Arab-Saudi Arabian 
9y/13y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD 
E, A, H, D, S, Dth, Sz 
Trauma C, P, T, Cs, Cb, Pq, Lactate 
Alive-normal 
2 
P22 7 Y Arab-Saudi Arabian 1y/4y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, D, S, Dth, Dph, Sz Viral infection C, P Alive-H, ID, D 14 
P23 7 Y-P24 Arab-Saudi Arabian 5,5y/6y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, T, D, S, Dth, Dph, Sz Viral infection C, P, T, Cs, Cb, Pq, SC Alive-S, ID 21 
P24 7 Y-P23 Arab-Saudi Arabian 47mo/4,08y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, D, S, Dth, Dph Viral infection C, P, T, Cs Alive-normal 0 
P25 7 Y Arab-Saudi Arabian 5y/10,08y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, D, S, Dth, Dph, Sz Viral infection C, P, T, Cs, Cb, Lactate Alive-A 2 
P26 7 Y Arab-Saudi Arabian 1y/5y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, D, S, Dth, Dph, Sz Viral infection C, P, T, Cs, Cb, B, Pq, SC, Lactate Alive-m, H, ID, D 28 
P27 7 Y Arab-Saudi Arabian 15y/20y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, H, D, S, Oph, Dth Trauma C, P, T Alive-normal, D 7 
P28 22 
N-P29 
White European-
Portuguese  
29y/25y c.74dupT/p.S26Lfs*19 c.980-14 A>G/p.G327Dfs*8 BTRBGD E, D, N, Dth, Dph, Sz Urinary tract 
infection 
C, P, GP, Cs 
Alive-D, S, Dth 
5 
P29 22 
N-P28 
White European-
Portuguese 
34y/40y c.74dupT/p.S26Lfs*19 c.980-14 A>G/p.G327Dfs*8 BTRBGD E, D, O, S, Oph, Dth, Dph, W Viral infection C, P, T, Cs, B 
Alive-D, S, Dth, ID 
23 
P30 28 
N-P31 White European-German 3y/- c.280 T>C/p.W94R 
c.1173-
3992_1314+41del4175/ 
p.Q393*fs 
BTRBGD E, A, Sd, O, S, Dth, Dph, Hep, Sz, D Viral infection C, P, T 
Deceased at 12y 
- 
P31 28 
N-P30 White European-German 9y/- c.280 T>C/p.W94R 
c.1173-
3992_1314+41del4175/ 
p.Q393*fs 
BTRBGD E, A, Sd, Ch, S, Dth, Dph, Res, Sz Viral infection C, P, T 
Deceased at 13y 
- 
P32 NR Y-P32 Arab-Moroccan 3.5y/9y c.1264G>A/p.T422A c.1264G>A/p.T422A BTRBGD E, H, T, Dth, Sz None C, P, T, Cs, Lactate Alive-S, ID, D 10 
P33 NR Y-P33 Arab-Moroccan 1.5y/13y c.1264G>A/p.T422A c.1264G>A/p.T422A BTRBGD E, H, T, Sz Gastroenteritis  C, P, Cs  Deceased at 13y - 
P34 29 N-P35, P36 Arab-Iraqi 19mo/4y c.157A>G/p.N53D c.157A>G/p.N53D LS E, A, H, D, Dth, Sb,   Pneumonia C, P, T, Cs, Cb, Pq, Lactate Alive-normal 0 
P35 NR 
N-P34, P36 
Arab-Iraqi Asymptomatic/ 
0,16y 
c.157A>G/p.N53D c.157A>G/p.N53D Asymptomatic Asymptomatic NA NA 
Alive-normal 
- 
P36 NR 
N-P34, P35 
Arab-Iraqi Asymptomatic/
0,16y 
c.157A>G/p.N53D c.157A>G/p.N53D Asymptomatic Asymptomatic NA NA 
Alive-normal 
- 
P37 29 
Y-P37 Arab-Kurdish 2y7mo/7y c.1264A>G/p.T422A c.1264A>G/p.T422A LS E, H, T, S, Dph, Dth, A Viral infection C, P, T, Lactate 
Alive-ID 
- 
P38 29 Y-P38 Arab-Kurdish 3mo/14y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, H, D, Dph, W,  None C, T, Cs Alive-ID, D 28 
P39 2 Y-P40, P41 Arab-Moroccan 1mo/0,08y c.20C>A/p.S7* c.20C>A/p.S7* LS NA NA NA Deceased at 1mo - 
P40 2 
Y-P39, P41 
Arab-Moroccan 
1mo/0,08y c.20C>A/p.S7* c.20C>A/p.S7* LS NA NA NA 
Deceased at 1mo 
- 
P41 2 
Y-P39, P40 
Arab-Moroccan 
1mo/0,11y c.20C>A/p.S7* c.20C>A/p.S7* LS E, H, T, D, O, Ak, S, N None NA 
Deceased at 6w 
- 
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P42 2 Y-P43 Arab-Moroccan 0,08y c.20C>A/p.S7* c.20C>A/p.S7* LS NA NA NA Deceased at 1mo - 
P43 2 
Y-P42 
Arab-Moroccan 
0,08y c.20C>A/p.S7* c.20C>A/p.S7* LS NA NA NA 
Deceased at 1mo 
- 
P44 2 
N-* 
Arab-Moroccan 
1mo/20y c.20C>A/p.S7* c.20C>A/p.S7* LS NA NA NA 
Deceased at 20y 
- 
P45 2 
N-* 
Arab-Moroccan 
1mo/15y c.20C>A/p.S7* c.20C>A/p.S7* LS NA NA NA 
Deceased at 15y 
- 
P46 NR N-P47 African/Afro-Caribbean 1mo/2mo c.91T>C/p.S31P c.516Het_delC/p.D173Tfs*35 LS E, H, D, O, S None P, GP, T, Cs, B Deceased at 2mo - 
P47 NR N-P46 African/Afro-Caribbean 1mo/0,75y c.91T>C/p.S31P c.516Het_delC/p.D173Tfs*35 LS E, H, T, D, O, S None P, GP, T, Cs, Cb, B Deceased at 9mo - 
P48 NR N White European-Finnish 1mo/2y c.541T>C/p.S181P c.541T>C/p.S181P LS E, H, T, D, Sd, Ch, O, S Viral infection P, T, Cs, Cs, Lactate Alive-H, m, D, ID 23 
P49 NR 
N White European-Finnish 3,5mo/3,5y c.541T>C/p.S181P c.833T>C/p.L278P LS E, H, T, D, Sd, O None C, P, GP, T, Cs, Cb, B 
Deceased at 3.5y 
- 
P50 26 Y-* Arab-Saudi Arabian 3y/7y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, Dth,  Viral infection C, P, Cs Alive-normal - 
P51 26 Y Arab-Saudi Arabian 3.5y/5y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD A Viral infection C, P, Cs Alive-normal - 
P52 26 
Y 
Arab-Saudi Arabian 
3mo/3y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, H, Sz None C, P, T, Cs, Cb, B 
Alive-H, ID, Sz 
- 
P53 26 
Y-* 
Arab-Saudi Arabian 
14mo/17y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD  D, S, Dth, Sz None C, P 
Alive-m, S, Sz, ID, 
D 
9 
P54 26 
Y-* 
Arab-Saudi Arabian 
5mo/14y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, D, S, Dth, Sz None C, P, Cs, Cb 
Alive-m, S, Sz, ID, 
D 
26 
P55 26 
N 
Arab-Saudi Arabian 
1y/7y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, D, S, Sb, Sz, Dth None C, P, T, Cs 
Alive-status not 
known  - 
P56 26 Y Arab-Saudi Arabian 5mo/4y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, H, Ch Vaccination C, P, Cb Alive-A, ID, H - 
P57 26 Y Arab-Saudi Arabian 3y/13y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, H, A, Dth, Sz None C, P, Cs, Pq Alive-S, Sch, D - 
P58 26 N-* Arab-Saudi Arabian 2y/24y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, S Viral infection C, P Alive-D - 
P59 26 Y-* Arab-Saudi Arabian 4y/25y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, A, Dth, Sz None C, P Alive-D, Sz - 
P60 26 Y-* Arab-Saudi Arabian 6y/13y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD S, Sz None C, P, Lactate Alive-normal - 
P61 26 
Y-* 
Arab-Saudi Arabian 
21mo/12y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD D, S, Dth, W, Sz None C, P, GP, Lactate 
Alive-S, Sz, H, ID, 
D 
29 
P62 26 Y-* Arab-Saudi Arabian 3y/4y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD A Viral infection C, P  Alive-normal - 
P63 26 Y-* Arab-Saudi Arabian 3.5y/8y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD A, Dth, MD None C, Cs Alive-normal - 
P64 26 Y Arab-Saudi Arabian 4mo/18mo c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, S, Dph, Hep, Sz Meningitis C, P, Cs, Cb Alive-Sz, ID, D - 
P65 26 Y Arab-Saudi Arabian 23mo/4y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD Rg, S, Dth, Dph Viral infection C, P, CA, CbA Alive-A, S, ID - 
P66 26 Y-* Arab-Saudi Arabian 3y/5y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD Dth None NA Alive-normal - 
P67 26 Y Arab-Saudi Arabian 3y/3y7mo c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD Rg None NA Alive-normal  - 
P68 30 Y-* Arab-Moroccan 3.5y/10y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, H, D, Sd, Ch, Sz, Dth Viral infection C, P, Cs, Lactate Alive-ID 0 
P69 30 Y Arab-Kuwaiti 9.5y/14y c.1264A>G/p.T422A c.1264A>G/p.T422A BTRBGD E, Oph, D, Sd, Dth  Viral infection C, P, T, Cs, Cb, SC Alive-normal 0 
P70 NR N White-Hispanic 23mo/27mo c.74dupT/p.S26Lfs*19 c.503_505delCGT/p.Y169* BTRBGD E, T, Pt, V, Dph, Dth, Dys, S Viral infection  C, P, Gp, T, Pq, Lactate Alive-normal - 
             
P71 5 
Y-P72, P73, P74 Arab-Israeli  6y/14y 
c.373G>A/p.G125S c.373G>A/p.G125S Bilateral striatal 
necrosis and 
neuropathy 
E, H, Dph, Dth 
Febrile illness 
C, P, 
Alive-Pn, ADHD,  
1 
P72 5 
Y-P71, P73, P74 Arab-Israeli 6.5y/14y 
c.373G>A/p.G125S c.373G>A/p.G125S Bilateral striatal 
necrosis and 
neuropathy 
E, H,  Febrile illness 
C, P, 
Alive-Pn, ADHD,  
1 
P73 5 
Y-P71, P72, P74 Arab-Israeli 3.5y/26y 
c.373G>A/p.G125S c.373G>A/p.G125S Bilateral striatal 
necrosis and 
neuropathy 
E, H, Sd, Dph, Dth Febrile illness 
C, P, 
Alive-Pn, MD 
6 
P74 5 
Y-P71, P72, P73 Arab-Israeli 4y/24y 
c.373G>A/p.G125S c.373G>A/p.G125S Bilateral striatal 
necrosis and 
neuropathy 
E, H, Sd, Dph, Dth Febrile illness 
C, P, T 
Alive-Pn, MD 
3 
P75 NR Y White European-German 20mo/21y c.580T>C/p.S194P c.580T>C/p.S194P Bilateral striatal 
necrosis 
E, T, D, O, V, A, Dph Otitis media C, P, Gp, Cs Alive -normal 0 
             
P76 9 
Y-P77 Asian-Chinese 6mo/- c604T>G/p.W202G c604T>G/p.W202G LS E,H,S, Hy, Dph, Res, Sz Viral infection C, P, GP, T, B, Pq, SC, Cb-dentate Deceased at 29 
mo 
- 
P77 9 Y-P76 Asian-Chinese 4mo/4y5mo c604T>G/p.W202G c604T>G/p.W202G LS E, H, D, S, Sb, Hy, Dph  Febrile illness P, T, Cb-dentate Alive – S, H, ID  23 
P78 NR N-* White European-Finnish 1mo/- c.365T>C/p.I122T c.365T>C/p.I122T LS  H, Hep, Sz N P, Gp, Cb-dentate Deceased at 6 mo - 
P79 10 
Y Indian 2,5y/7y c.479C>T/p.S160L c.479C>T/p.S160L LS S Viral infection Cb-dentate Alive – S, MD, M, 
ID 
14 
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Supplementary Table 1. Demographic, clinic, genetic and radiologic features of 78 
patients with SLC19A3, SLC25A19 and TPK1 deficiency 
*Other sibling affected not included in this study, NA = Not available, SYMPTOMS 
AT ONSET/ OUTCOME: Encephalopathy (E), Paroxysmal Ataxia (A), Hypotonia 
(H), Tremor (T), Dystonia (D), Status dystonicus (Sd), Chorea (Ch), Opistothonus (O), 
Rigidity (Akinetic-rigid syndrome) (Ak), Spasticity (S), Nystagmus (N), Strabismus 
(Sb), Ptosis (Pt), Ophtalmoplegia (Oph), Diplopia (D), Vertigo (V), Hypoaesthesia (Hy) 
Dysarthria (Dth), Dysphagia (Dph), Weight loss (W), Respiratory failure (Res), Liver 
disease (Hep), Rhabdomyolisis (Rab), Dysautonomia (Dys), Jaundice (J), Seizure – 
including focal, generalized and infantile spasms (Sz), Peripheral neuropathy  (Pn), 
Developmental arrest (Rg), Movement disorder (MD), Spasticity (S), Intellectual 
disability (ID), Scoliosis (Sch), microcephaly (m).  ABNORMAL REGIONS ON 
NEUROIMAGING: Caudate (C), Putamen (P), Globus pallidus (Gp), Thalamus (T), 
Corticosubcortical (Cs), Cerebellum (Cb), Brainstem (B), Periqueductal (Pq), Spinal 
cord  (SC), Lactate on MRS (Lactate), Cerebral atrophy (CA), Cerebellar atrophy 
(CbA). PHENOTYPES Leigh Syndrome (LS), Biotin responsive basal ganglia disease 
(BTRBGD), Asymptomatic 
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Reference of patients with PDHc deficiency  
To identify previously published PDHc deficiency cases a systematic literature search 
was conducted in PubMed in January 2017 using the search terms “Pyruvate 
dehydrogenase complex deficiency”, “pyruvate dehydrogenase complex”, “PDHA1”, 
“PDHB” and “PDHX”.  The search was limited to studies in humans published after 
1.1.1990 (considering availability in our electronic library). We restricted the search to 
articles in English. 75 full-text records were retrieved, describing 324 cases with PDHc 
deficiency. The cases were used to ascertain genotypes, sex and for Kaplan- Meier 
survival analysis. 
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Figure 1. Thiamine metabolism  
 
243x182mm (300 x 300 DPI)  
 
 
Page 51 of 61
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
  
 
 
Figure 2. Clinical feature and MRI  
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Figure 3. MRI patterns in patients with secondary and inherited thiamine defects.  
 
170x126mm (300 x 300 DPI)  
 
 
Page 53 of 61
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
  
 
 
Figure 4. Kaplan cruves and timeframe  
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Figure 5. Pathogenic mutations  
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Figure 6. Inherited thiamine defects  
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Table 1. Suggested criteria for the diagnosis of inherited thiamine defects with 
prominent neurologic involvement  
Required 
1. Clinical criteria  
a. SLC19A3: Acute or recurrent episodes of encephalopathy (decreased 
consciousness, irritability) with 2 or more of the following: 1) dystonia, 2) 
hypotonia, 3) bulbar dysfunction, 4) ataxia and 5) seizures. Of note 16% of 
patients may have an insidious onset of symptoms (psychomotor 
regression, clumsy or abnormal gait, stiff limbs). 
b. SLC25A19: Acute or recurrent episodes of encephalopathy with: 1) 
progressive peripheral neuropathy, or 2) severe congenital microcephaly 
with brain malformations.  
c. TPK1: Acute or recurrent episodes of encephalopathy, with 2 or more of 
the following: 1) dystonia, 2) hypotonia, 3) ataxia, 4) seizures and 5) 
developmental delay. Of note some patients may have a non-episodic early 
onset global developmental delay.    
2. Biochemical criteria  
a. Normal total thiamine blood levels 
b. Low free-thiamine in CSF and/or fibroblasts (SLC19A3) 
c. Low TDP in blood, muscle and/or fibroblasts (TPK1)  
d. High excretion of alpha-ketoglutaric acid in urine (common in TPK1 and 
SLC25A19, rare in SLC19A3). 
3. Radiological criteria  
a. MRI pattern compatible with Leigh syndrome (SLC19A3, SLC25A19, TPK1) 
or Wernicke  encephalopathy (SLC19A3) 
i. SLC19A3: Symmetrical T2W hyperintensity of caudate, putamen, 
cortico-subcortical areas and/or ventromedial thalamus. No 
involvement of mammillary bodies.  
ii. SLC25A19: Symmetrical T2W hyperintensity in the caudate and 
putamen.  
iii. TPK1: Symmetrical T2W hyperintensity in basal ganglia and 
cerebellum (dentate nuclei).  
4. Therapeutic criteria 
a. Clinical improvement after thiamine supplementation. 
Supportive 
1. Consanguinity  
2. Trigger event (infection, vaccination, trauma, intense physical activity, etc.). 
3. Absence of predisposing factors of beriberi or Wernicke encephalopathy. 
4. Absence of systemic features of mitochondrial disease (cardiomyopathy, 
arrhythmia/conduction defects, renal tubulopathy or dysmorphic features). 
5. Increased lactate in blood and/or CSF.  
6. Normal OXPHOS and PDHc activity in muscle and fibroblast.  
7. Increased lactate on MRS. 
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Figure 1. Thiamine metabolism (Black and White version)  
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Figure 2. Clinical features and MRI (Black and White version)  
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Figure 5. Pathogenic mutations (Black and White version)  
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(B&W) Figure 6. Inherited thiamine defects  
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